Reducing Post-Hospital Mortality in HIV-infected Adults in Tanzania

Sponsor
Weill Medical College of Cornell University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03858998
Collaborator
National Institute of Mental Health (NIMH) (NIH)
500
16
2
50.9
31.3
0.6

Study Details

Study Description

Brief Summary

This research is being done to assess the efficacy of a case management intervention to improve the one year mortality rate of hospitalized, HIV-infected, Tanzanian adults.

Condition or Disease Intervention/Treatment Phase
  • Other: Case Management Intervention
  • Other: Control
N/A

Detailed Description

This research is being done to assess the efficacy of a case management intervention to improve the one year mortality rate of hospitalized, HIV-infected, Tanzanian adults. The study is being conducted at hospitals in Mwanza, Tanzania. 500 participants will be enrolled: 250 will be randomized to the case management intervention and 250 will randomized to routine clinical care. The case management intervention consists of 5 sessions over 90 days, and is designed to link hospitalized, HIV-infected patients to long term care at an HIV clinic. Participants will be followed for two years in order to evaluate primary and secondary study objectives.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
500 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Reducing Post-Hospital Mortality in HIV-infected Adults in Tanzania
Actual Study Start Date :
Mar 5, 2019
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
May 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Case Management Intervention

A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.

Other: Case Management Intervention
A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.

Other: Control
Current routine HIV care in Tanzania.

Other: Control

Current routine HIV care in Tanzania.

Other: Control
Current routine HIV care in Tanzania.

Outcome Measures

Primary Outcome Measures

  1. Number of participant deaths in the first 12 months post-hospitalization [12 months]

    The number of participants who die in the first 12 months post-hospitalization will be recorded. Death will be determined by phone calls to relatives and will be confirmed by verbal autopsies, obituaries, hospital records, or death certificates.

Secondary Outcome Measures

  1. Number of participants who attended HIV clinic [3, 6, 9, and 12 months]

    HIV clinic attendance will be monitored by review of HIV clinic records. HIV clinic attendance is defined as alive and attended clinic within a window of 90 days (+/- 45 days) around the time points.

  2. ART adherence [3, 6, 9, and 12 months]

    ART adherence will be assessed using the ACTG 4-Day ART Recall Questionnaire. Adherence will be calculated as a percentage, using 1 - (number of missed doses/number of prescribed doses).

  3. Viral suppression [12 months]

    Suppressed viral load will be defined as a binary outcome based upon the WHO definition of viral suppression as a plasma HIV-1 RNA level <1000 copies/µl.

  4. Traditional Health Beliefs [Baseline and 12 months]

    Traditional health beliefs will be assessed at baseline and after 12 months using the HIV Insights and Beliefs Scale, scored from 0 to 6, where higher scores indicate more traditional health beliefs.

  5. Self-Efficacy [Baseline and 12 months]

    Self-efficacy will be assessed at baseline and after 12 months using the HIV Adherence Self-Efficacy Scale, scored from 0 to 25, where higher scores indicate a higher level of self-efficacy.

  6. Stigma [Baseline and 12 months]

    Stigma will be assessed at baseline and after 12 months using questions based off the AIDS-Related Stigma Scale, scored from 0 to 8, where higher scores indicate a higher level of perceived stigma.

  7. Social Support [Baseline and 12 months]

    Social support will be assessed at baseline and after 12 months using the SPS-10 Scale, scored from 0 to 40, where higher scores indicate a higher level of social support.

  8. Perceived Need for HIV Services [Baseline and 12 months]

    Perceived need for HIV services will be assessed at baseline and after 12 months using the ART Medications Attitude Scale, scored from 0 to 4, where higher scores indicate a lower perceived need for HIV services.

  9. Physical Weakness [Baseline and 12 months]

    Physical weakness will be assessed at baseline and after 12 months using the SF-12 Health Survey. The SF-12 measures physical health, scored from 0 to 100, with higher scores indicating greater physical health.

  10. Acceptability [12 months]

    Qualitative interviews will be conducted with a sub-set of participants to evaluate the acceptability of the intervention. The sub-set will be comprised of 20 intervention participants, 20 routine care control participants, and 20 healthcare workers (nurses and physicians). The interviews will be conducted by trained qualitative research assistants and will focus on the issues central to the intervention including traditional health beliefs, self-efficacy, stigma, social support, and perceived need for HIV services.

  11. Incremental cost of the intervention [12 months]

    Healthcare service utilization will be summarized for each arm as descriptive counts such as number of HIV care visits, home visits, laboratory tests, medications, and hospitalizations. Unit costs will be determined for each type of service unit by applying labor rates and materials costs available from the study hospital, and other expense costs available from previous studies. Unit costs will be multiplied by service utilization to calculate healthcare costs. Resources spent on research activities will be excluded. Costs will be reported from the healthcare sector perspective. All data will be analyzed under an intent-to-treat principle.

  12. Cost per life saved [12 months]

    The difference in costs between the arms from the healthcare perspective will be compared to the observed difference in survival between the arms to calculate incremental cost per life saved. Parametric methods based on parameters obtained from bootstrapping will be used to estimate an acceptability curves, which will illustrate the probability that the intervention is a good value for different willingness-to-pay thresholds

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years of age or older

  • HIV-infected

  • ART (anti-retroviral therapy) naïve or have been on ART but have not used ART for > 7 days

  • Lives in the region of Mwanza

  • Able to be referred to an HIV clinic inside the region of Mwanza

  • Has mobile phone or access to mobile phone

  • Planning to stay in the region of Mwanza for the next 24 months

  • Able to speak Kiswahili or English

  • Capable and willing to provide informed consent

  • Willing to provide locator information and two designated contact persons

  • Willing to have a home visits from a study team member

Exclusion Criteria

  • Pregnant

  • On anti-retrovirals at hospital admission and already linked to an HIV clinic

  • Medical, psychiatric or psychological condition that, in the opinion of the site investigator, would interfere with completion of study procedures

Contacts and Locations

Locations

Site City State Country Postal Code
1 Busisi Health Center Busisi Mwanza Tanzania
2 Magu District Hospital Magu Mwanza Tanzania
3 Nyamilama Health Center Nyamilama Mwanza Tanzania
4 Sengerema Health Center Sengerema Mwanza Tanzania
5 Bugando Medical Center Mwanza Tanzania
6 Bukumbi Hospital Mwanza Tanzania
7 Buzuruga Health Center Mwanza Tanzania
8 Evangelical Lutheran Church in Tanzania (ELCT) Health Centre Mwanza Tanzania
9 Igoma Health Centre Mwanza Tanzania
10 Karume Health Centre Mwanza Tanzania
11 Kwimba District Hospital Mwanza Tanzania
12 Misungwi District Hospital Mwanza Tanzania
13 Nyamagana District Hospital Mwanza Tanzania
14 Sekou Toure Hospital Mwanza Tanzania
15 Sengerema District Hospital Mwanza Tanzania
16 Seventh Day Adventist (SDA) Health Centre Mwanza Tanzania

Sponsors and Collaborators

  • Weill Medical College of Cornell University
  • National Institute of Mental Health (NIMH)

Investigators

  • Principal Investigator: Robert Peck, MD, Weill Medical College of Cornell University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT03858998
Other Study ID Numbers:
  • 1804019134
  • R01MH118107-01
First Posted:
Mar 1, 2019
Last Update Posted:
Mar 11, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 11, 2022